Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Cantharidin Combined with Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer

  • Han, Li (Department of Traditional Chinese Medicine, Huadong Hospital of Fudan University) ;
  • Sun, Yi-Jie (Department of Traditional Chinese Medicine, Huadong Hospital of Fudan University) ;
  • Pan, Yong-Fu (Department of Traditional Chinese Medicine, Huadong Hospital of Fudan University) ;
  • Ding, Hao (Department of General Surgery, Huadong Hospital of Fudan University) ;
  • Chen, Xi (Department of Oncology, Huadong Hospital of Fudan University) ;
  • Zhang, Xu (Department of Traditional Chinese Medicine, Huadong Hospital of Fudan University)
  • Published : 2015.01.22
Download PDF
⟨ Previous Next ⟩

Abstract

Background: This systematic analysis was conducted to evaluate the efficacy and safety of cantharidin combined with chemotherapy in treating Chinese patients with metastatic colorectal cancer. Methods: Clinical studies evaluating the efficacy and safety of cantharidin combined with chemotherapy on response and safety for Chinese patients with colorectal cancer were identified using a predefined search strategy. Pooled response rate (RR) of treatment were calculated.Results: When cantharidin combined with chemotherapy, 4 clinical studies which included 155 patients with advanced colorectal cancer were considered eligible for inclusion. The systematic analysis suggested that, in all patients, pooled RR was 46.5% (72/155) in cantharidin combined regimens. Major adverse effects were neutropenia, leukopenia, fatigue, and anemia with cantharidin combined treatment; no treatment related deaths occurred. Conclusion: This systematic analysis suggests that cantharidin combined regimens are associated with high response rate and accepted toxicity in treating Chinese patients with metastatic colorectal cancer suggesting that randomized clinical trials are now warranted.

Keywords

References

  1. Andre T, Louvet C, Maindrault-Goebel F, et al (1999). CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer, 35, 1343-7. https://doi.org/10.1016/S0959-8049(99)00150-1
  2. Bajetta E, Di Bartolomeo M, Mariani L, et al (2004). Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer, 100, 279-87. https://doi.org/10.1002/cncr.11910
  3. Bajsa J, Pan Z, Duke SO (2011). Transcriptional responses to cantharidin, a protein phosphatase inhibitor, in Arabidopsis thaliana reveal the involvement of multiple signal transduction pathways. Physiol Plant, 143, 188-205. https://doi.org/10.1111/j.1399-3054.2011.01494.x
  4. Borner MM, Bernhard J, Dietrich D, et al (2005). A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol, 16, 282-8. https://doi.org/10.1093/annonc/mdi047
  5. Cartwright T, Lopez T, Vukelja SJ, et al (2005). Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer, 5, 50-6. https://doi.org/10.3816/CCC.2005.n.016
  6. Chen HJ, Wu AG (2004). A clinical study on cantharidin combined with 5-Fu/CF in treating patients with advanced colorectal cancer. J Chinese Doctor.
  7. De Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47.
  8. De Gramont A, Kindler HL (2002). Pemetrexed in patients with gastrointestinal carcinoma. Semin Oncol, 29, 42-9. https://doi.org/10.1053/sonc.2002.30763
  9. Douillard JY, Cunningham D, Roth AD, et al (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355, 1041-7. https://doi.org/10.1016/S0140-6736(00)02034-1
  10. Douillard JY, Cunningham D, Roth AD, et al (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone. As first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 25, 1041-7.
  11. Fan LJ (2009). A clinical observation on Cantharidin B6 5-Fu and CF in treating patients with advanced colorectal cancer. Mod Med J China, 11, 64-5
  12. Fan QL, Wang Y (2013). A clinical study on Cantharidin B6 and S-1 in treating patients with advanced gastrointestinal cancer. Guang Ming Chin Med, 28, 4.
  13. Fuchs CS, Marshall J, Mitchell E, et al (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol, 25, 4779-86. https://doi.org/10.1200/JCO.2007.11.3357
  14. Garcia-Alfonso P, Munoz-Martin A, Mendez-Urena M, et al (2009). Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer, 101, 1039-43. https://doi.org/10.1038/sj.bjc.6605261
  15. He F, Fan T (2014). Cantharidin and mFOLFOX6 in treating patients with colorectal cancer. J Med Sci Central South China, 3, 311-3
  16. Hsieh CH, Huang YC, Tsai TH, et al (2011). Cantharidin modulates development of human monocyte-derived dendritic cells. Toxicol In Vitro, 25, 1740-7. https://doi.org/10.1016/j.tiv.2011.09.001
  17. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90 https://doi.org/10.3322/caac.20107
  18. Kohne CH, De Greve J, Hartmann JT, et al (2008). Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol, 19, 920-6. https://doi.org/10.1093/annonc/mdm544
  19. Kohne CH, Van Cutsem E, Wils J, et al (2005). Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol, 23, 4856-65. https://doi.org/10.1200/JCO.2005.05.546
  20. Liu D, Chen Z (2009). The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem, 9, 392-6. https://doi.org/10.2174/1871520610909040392
  21. Miwa M, Ura M, Nishida M, et al (1998). Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, 34, 1274-81. https://doi.org/10.1016/S0959-8049(98)00058-6
  22. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  23. Patt YZ, Lee FC, Liebmann JE, et al (2007). Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol, 30, 350-7. https://doi.org/10.1097/COC.0b013e31804b40bb
  24. Saltz LB, Cox JV, Blanke C, et al (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl J Med, 343, 905-14. https://doi.org/10.1056/NEJM200009283431302
  25. Shanghai municipal center for disease control and prevention: Shanghai Cancer Report 2007.
  26. Van Cutsem E, Findlay M, Osterwalder B, et al (2000). Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol, 18, 1337-45.
  27. Van Cutsem E, Nordlinger B, Adam R, et al (2006). Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer, 42, 2212-21. https://doi.org/10.1016/j.ejca.2006.04.012
  28. Verma AK, Prasad SB (2012). Bioactive component, cantharidin from Mylabris cichorii and its antitumor activity against Ehrlich ascites carcinoma. Cell Biol Toxicol, 28, 133-47. https://doi.org/10.1007/s10565-011-9206-6
  29. Wang L, Huang XE, Cao J (2014). Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively. Asian Pac J Cancer Prev, 15, 5597-600 https://doi.org/10.7314/APJCP.2014.15.14.5597
  30. Xu Y, Zhao AG, Li ZY (2012). Survival benefit of traditional chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancer. Integr Cancer Ther, 9, 9.
  31. Yoo PS, Lopez-Soler RI, Longo WE, et al (2006). Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer, 6, 202-7. https://doi.org/10.3816/CCC.2006.n.036
  32. Zhan YP, Huang XE, Cao J (2012). Clinical study on safety and efficacy of $Qinin^{(R)}$ (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pacific J Cancer Prev, 13, 4773-6 https://doi.org/10.7314/APJCP.2012.13.9.4773

Cited by

  1. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer vol.9, pp.1, 2015, https://doi.org/10.5582/bst.2015.01019